Kamal, Kanika
Xiang, David H.
Young, Katherine
Mostaghimi, Arash
Barbieri, John S.
Cohen, Jeffrey M.
Theodosakis, Nicholas
Article History
Received: 4 December 2023
Revised: 4 December 2023
Accepted: 14 December 2023
First Online: 22 January 2024
Declarations
:
: A.M. receives consulting fees from Pfizer, hims, Digital Diagnostics, Concert, Lilly, Abbvie, Equillium, and Boehringer Ingelheim. A.M. also owns equity in hims, Fig. 1, Acom, Seebe. He receives licensing fees and royalties from Pfizer, Concert, and Lilly. He serves on the medical advisory board for hims, Fig. 1, and Digital Diagnostics. A.M. oversees clinical trials for Lilly and Concert. J.M.C. serves on a data and safety moniroting board (DSMB) for Advarra. J.S.B. is an associate editor for JAMA Dermatology.
: This study was deemed exempt by the Yale School of Medicine Institutional Review Board.
: Not applicable, as research has been deemed as non-human subject research.